Allarity Therapeutics (NASDAQ:ALLR) Issues Q4 2026 Earnings Guidance

Allarity Therapeutics (NASDAQ:ALLR) updated its fourth quarter 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.010-0.040 for the period, compared to the consensus earnings per share estimate of -0.210. Allarity Therapeutics also updated its FY 2026 guidance to -0.760–0.730 EPS.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $10.25.

Allarity Therapeutics Price Performance

Allarity Therapeutics stock opened at $0.91 on Friday. The firm has a market cap of $14.54 million, a PE ratio of -1.17 and a beta of 0.57. The stock’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $1.21. Allarity Therapeutics has a one year low of $0.77 and a one year high of $1.84.

Allarity Therapeutics (NASDAQ:ALLR) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.18). The company had revenue of $0.01 million for the quarter. Allarity Therapeutics has set its FY 2026 guidance at -0.760–0.730 EPS and its Q4 2026 guidance at 0.010-0.040 EPS. Sell-side analysts expect that Allarity Therapeutics will post -0.80 earnings per share for the current fiscal year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.